ADCC-Enhanced Anti-Human PD-L1 (CS1001) Antibody (CAT#: BioBet-CB-026LX) Datasheet

CD274 molecule

CD274 molecule

This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]

CD274 molecule

Cell Biology, Immunology,

Protein Based Therapies
Monoclonal antibody (mAb)

IgG4

CS1001

Human

Human

ADCC-Enhanced Anti-Human PD-L1 (CS1001) Antibody is derived from clone CS1001, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the PD-L1, and it is intended for the research of Non-small cell lung cancer.

Non-small cell lung cancer

Similar to the parental antibody CS1001, ADCC-Enhanced Anti-Human PD-L1 (CS1001) Antibody targets to the antigen PD-L1, achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.